On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Thierry Naas

ResearcherPublications, citations & collaboration network

Thierry Naas is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Thierry Naas have?

ScholarIQindexed works

Thierry Naas has 479 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Thierry Naas have?

ScholarIQcitation count

Thierry Naas has 29,337 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Thierry Naas?

ScholarIQh-index

Thierry Naas has an h-index of 79 in OpenAlex.

What is the i10-index of Thierry Naas?

ScholarIQi10-index

Thierry Naas has an i10-index of 323 in OpenAlex.

What is the ORCID of Thierry Naas?

ScholarIQorcid

The ORCID for Thierry Naas is on the source record.

What is the OpenAlex record for Thierry Naas?

ScholarIQopenalex

The OpenAlex for Thierry Naas is on the source record.

What are the most-cited papers on Thierry Naas?

ScholarIQmost cited works
Global Spread of Carbapenemase-producing<i>Enterobacteriaceae</i>
Patrice Nordmann, Thierry Naas, Laurent Poirel
Emerging infectious diseases. 20112,352 CitationsOPEN ACCESS
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Patrice Nordmann, Gaëlle Cuzon, Thierry Naas
The Lancet Infectious Diseases. 20091,587 Citations
High Frequency Retrotransposition in Cultured Mammalian Cells
John V. Moran, Susan E. Holmes, Thierry Naas, Ralph J. DeBerardinis, Jef D. Boeke, Haig H. Kazazian
Cell. 19961,041 CitationsOPEN ACCESS
Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe
Rafael Cantón, Murat Akova, Yehuda Carmeli, Christian G. Giske, Y. Glupczynski, Marek Gniadkowski, David M. Livermore, Vivì Miriagou, Thierry Naas, Gian María Rossolini, Ørjan Samuelsen, Harald Seifert, Neil Woodford, Patrice Nordmann
Clinical Microbiology and Infection. 2012883 CitationsOPEN ACCESS
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti, Roger Echols, Yuko Matsunaga, Mari Ariyasu, Yohei Doi, Ricard Ferrer, Thomas P. Lodise, Thierry Naas, Yoshihito Niki, David L. Paterson, Simon Portsmouth, Julián Torre‐Cisneros, Kiichiro Toyoizumi, Richard G. Wunderink, Tsutae Den Nagata
The Lancet Infectious Diseases. 2020810 Citations

Related on ScholarIQ

470M+ articles · 14-day free trial